Biotechnology
Medical
Biopharmaceutical

Alder BioPharmaceuticals

$9.76
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.29 (-2.87%) Today
-$0.06 (-0.61%) As of 7:37 PM EDT after-hours

Why Robinhood?

You can buy or sell ALDR and other stocks, options, ETFs, and crypto commission-free!

About ALDR

Alder BioPharmaceuticals, Inc. Common Stock, also called Alder BioPharmaceuticals, is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Read More Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.

Employees
202
Headquarters
Bothell, Washington
Founded
2004
Market Cap
817.48M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
887.41K
High Today
$10.24
Low Today
$9.78
Open Price
$10.13
Volume
984.34K
52 Week High
$20.87
52 Week Low
$9.44

Collections

Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Health
Therapy
Technology
2014 IPO

ALDR Earnings

-$1.73
-$1.42
-$1.11
-$0.80
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.